PepGen Past Earnings Performance

Past criteria checks 0/6

PepGen's earnings have been declining at an average annual rate of -56.2%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

-56.2%

Earnings growth rate

19.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-72.5%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

PepGen: Long Road Ahead

Jan 20

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Nov 13
Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Jul 31
Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Dec 31
We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07
Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Revenue & Expenses Breakdown
Beta

How PepGen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PEPG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-791768
30 Sep 230-741665
30 Jun 230-691660
31 Mar 230-671558
31 Dec 220-691454
30 Sep 220-611345
30 Jun 220-511235
31 Mar 220-391024
31 Dec 210-27819
30 Sep 210-23615
30 Jun 210-1549
31 Mar 210-1026
31 Dec 200-411

Quality Earnings: PEPG is currently unprofitable.

Growing Profit Margin: PEPG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PEPG is unprofitable, and losses have increased over the past 5 years at a rate of 56.2% per year.

Accelerating Growth: Unable to compare PEPG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PEPG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: PEPG has a negative Return on Equity (-72.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.